Bill Snyder

VUMC-led team isolates antibody that blocks bird flu

VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans.

Study examines HIV drug’s potential to treat Alzheimer’s

A drug used to treat and prevent HIV/AIDS is showing promise as a potential therapy for Alzheimer’s disease.

VUMC’s Denny selected to lead national ‘All of Us’ program

The National Institutes of Health (NIH) has selected Joshua Denny, MD, MS, vice president of Personalized Medicine at Vanderbilt University Medical Center, to be the chief executive officer of the federal All of Us Research Program.

Study reveals mysteries of critical brain receptor complex

Poorly functioning AMPARs have been linked to a wide range of neurological and psychiatric disorders including seizures, Alzheimer’s disease, major depression and autism spectrum disorder. Understanding how AMPARs are formed and operate is essential for the rational design of pharmacological compounds that, by tuning AMPAR activity up or down, could improve treatment of these conditions.

Study finds ‘frozen’ fear response may underlie PTSD

To explore how fear becomes entrenched, VUMC researchers traveled down the precise neuronal pathways in the brains of mice that trigger fear responses, and which normally extinguish the behaviors once the danger has passed.

Max Joffe, PhD, left, P. Jeffrey Conn, PhD, and colleagues are studying a new class of antidepressants that may relieve symptoms more rapidly and with fewer side effects.

Study explores potential new class of antidepressants

Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications.

1 47 48 49 50 51 116